{"id":6120,"date":"2019-10-07T13:23:47","date_gmt":"2019-10-07T07:53:47","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6120"},"modified":"2025-05-08T11:55:23","modified_gmt":"2025-05-08T06:25:23","slug":"a-new-era-for-migraine-treatment-and-cgrp-antibodies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies","title":{"rendered":"A New Era for Migraine Treatment and CGRP antibodies"},"content":{"rendered":"\n

The World Health Organization\u2019s disability rating for migraine ranks it as the 19th most common reason for disability.<\/strong><\/p>\n\n\n\n

According to the Migraine Trust Organization,\nMigraine is ranked as the 7th most disabling disease in the world (a cause for\na loss of 2.9% of all years of life lost to disability\/YLDs).<\/p>\n\n\n\n

The Global Burden of Disease 2016 report labels\nmigraine to be the third most common and second most debilitating disease.<\/p>\n\n\n\n

Migraine is a highly prevalent headache disease\naffecting about 14% of the global population or one billion people worldwide.\nWith one in five women suffering from migraine in their lifetime, compared to\none man in 16, it typically affects the most productive years of life. It\nusually starts at puberty and mostly affects between 35 and 45 years, but it\ncan trouble much younger generation, including children.<\/p>\n\n\n\n

According to the Migraine Research Foundation,\nhealthcare and lost productivity costs associated with migraine are estimated\nto be as high as USD 36 billion annually in the U.S. There is no known cause\nfor migraine, although most people with migraine are genetically predisposed to\nit.<\/p>\n\n\n\n

The new face of the Migraine treatment landscape <\/strong><\/h4>\n\n\n\n

There is an improvement in the understanding of the\nmigraine pathophysiology. Improved characterization and diagnosis of the\nclinical features and the availability of severity-based medications to treat\nmigraine have contributed in fuelling Migraine therapy market.<\/p>\n\n\n\n

For effective Migraine treatment<\/a><\/strong>, the correct diagnosis and choice of treatment become imperative. Taking into account the severity and frequency of attacks, other symptoms, patient preference, history of treatment, and comorbid conditions, Migraine treatment has almost always relied on re-purposing medication. However, the past decade has experienced tremendous research to cure migraine and find breakthroughs in migraine therapy market.<\/p>\n\n\n\n

One such novel way that has played a significant\nrole in the march towards the goal is inflammatory neuropeptide Calcitonin\nGene-Related Peptide (CGRP).<\/p>\n\n\n\n

In May 2018, Aimovig (erenumab) became the first\npreventive treatment of migraine in adults. It blocks the calcitonin\ngene-related peptide receptor (CGRP-R), which is believed to play a critical\nrole in migraine. Fremanezumab (Ajovy), Teva Pharmaceutical\u2019s drug was approved\nin September 2018 for preventing migraine and became the second migraine drug\ntargeting calcitonin gene-related peptide (CGRP) to reach the market.<\/p>\n\n\n\n

The migraine market<\/a><\/strong> is expected to grow in the coming years due to increasing female population and rise in the prevalence of migraine.<\/p>\n\n\n\n

Organizations like the American Headache and\nMigraine Association are taking initiatives to spread awareness, and also\nvarious emerging treatments will undoubtedly boost the growth of the global\nmigraine drug market in the forecast period.<\/p>\n\n\n\n

Migraine Treatments and Unmet needs<\/strong><\/h4>\n\n\n\n

The migraine field has recently been experiencing an\noutburst of novel, specifically-designed acute and preventive treatment\nmethods, reflecting advances in the understanding of this disorder and better\nacknowledgement of its detrimental global impact on sufferers\u2019 quality of lives.<\/p>\n\n\n\n

After the recommendation of Erenumab and\nFremanezumab, there lies a wide scope of more studies to fully understand the\nclinical potential, long-term safety, and cost-effectiveness of these\ntherapies. There is a substantial unmet need in the current migraine treatment\noptions that can be summarized into efficacy, tolerability issues, and lack of\nmigraine-specific treatments besides the triptans. This will facilitate the\ndevelopment of treatments with the patients facing high unmet medical need.<\/p>\n\n\n\n

Migraine Pipeline <\/strong><\/h4>\n\n\n\n

Key pharma players, such as Axsome Therapeutics, IMPAX Laboratories, Inc., Impel NeuroPharma, Zosano Pharma Corporation, Biohaven Pharmaceuticals, Inc., Allergan, and many others are investing themselves in developing Migraine therapies. The upcoming launch of Migraine emerging therapies, such as INP104 by Impel NeuroPharma, AXS-07 of Axsome Therapeutics, M207\/ADAM Zolmitriptan under trials by Zosano Pharma Corporation, Rimegepant (Biohaven Pharmaceuticals), and Allergen’s Ubrogepant is anticipated to create a considerable increase in the Migraine market size in the upcoming years.<\/p>\n","protected":false},"excerpt":{"rendered":"

The World Health Organization\u2019s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability\/YLDs). The Global Burden of […]<\/p>\n","protected":false},"author":1,"featured_media":6123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[70,17796,1193,6441,6439,17795],"industry":[17225],"therapeutic_areas":[17229],"class_list":["post-6120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-allergan","tag-biohaven-pharmaceuticals","tag-migraine","tag-migraine-therapy","tag-migraine-treatment","tag-zosano-pharma-corporation","industry-pharmaceutical","therapeutic_areas-central-nervous-system"],"acf":[],"yoast_head":"\nMigraine Treatment Market and Trends | DelveInsight<\/title>\n<meta name=\"description\" content=\"A novel way that has played a significant role in fuelling Migraine treatment landscape is inflammatory neuropeptide Calcitonin Gene-Related Peptide (CGRP).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Migraine Treatment Market and Trends | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"A novel way that has played a significant role in fuelling Migraine treatment landscape is inflammatory neuropeptide Calcitonin Gene-Related Peptide (CGRP).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-07T07:53:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:25:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Migraine Treatment Market and Trends | DelveInsight","description":"A novel way that has played a significant role in fuelling Migraine treatment landscape is inflammatory neuropeptide Calcitonin Gene-Related Peptide (CGRP).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies","og_locale":"en_US","og_type":"article","og_title":"Migraine Treatment Market and Trends | DelveInsight","og_description":"A novel way that has played a significant role in fuelling Migraine treatment landscape is inflammatory neuropeptide Calcitonin Gene-Related Peptide (CGRP).","og_url":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-07T07:53:47+00:00","article_modified_time":"2025-05-08T06:25:23+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies","url":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies","name":"Migraine Treatment Market and Trends | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp.jpg","datePublished":"2019-10-07T07:53:47+00:00","dateModified":"2025-05-08T06:25:23+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A novel way that has played a significant role in fuelling Migraine treatment landscape is inflammatory neuropeptide Calcitonin Gene-Related Peptide (CGRP).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp.jpg","width":772,"height":482,"caption":"Migraine Treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/18214456\/cgrp-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biohaven Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Migraine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Migraine therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Migraine treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Zosano Pharma Corporation<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Biohaven Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Migraine<\/span>","<span class=\"advgb-post-tax-term\">Migraine therapy<\/span>","<span class=\"advgb-post-tax-term\">Migraine treatment<\/span>","<span class=\"advgb-post-tax-term\">Zosano Pharma Corporation<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Oct 7, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Oct 7, 2019 1:23 pm","modified":"Updated on May 8, 2025 11:55 am"},"featured_img_caption":"Migraine Treatment ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6120"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6120\/revisions"}],"predecessor-version":[{"id":31890,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6120\/revisions\/31890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6123"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6120"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6120"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}